U.S. Stock Market Midday Update
Tharimmune fell 21.69%, with increased trading volume. According to recent key news:
<ol>
<li>
On September 18, Tharimmune announced that its main drug failed to meet expectations in clinical trials, leading to a loss of investor confidence and a significant drop in stock price.
</li>
<li>
On September 17, rumors emerged that Tharimmune might face regulatory investigations, increasing market uncertainty and further pressuring the stock price.
</li>
<li>
On September 16, a competitor of Tharimmune released more positive clinical trial results, attracting investor attention and putting pressure on Tharimmune's stock price. The biotechnology industry has been highly volatile recently.
</li>
</ol>
Top Stocks by Industry Trading Volume
Metsera rose 62.76%, with a trading volume of $494 million. According to recent key news:
<ol>
<li>
On September 22, Pfizer announced it would acquire Metsera for $4.9 billion, offering $47.50 per share in cash, a 43% premium over last Friday's closing price. If certain performance milestones are met, an additional $22.50 per share will be paid, bringing the total transaction value to a maximum of $7.3 billion. This news drove Metsera's stock price significantly higher.
</li>
<li>
On September 22, Metsera's stock price rose over 60% in pre-market trading, reaching $53.46. The acquisition news from Pfizer sparked a strong market reaction, with investors optimistic about Metsera's future performance.
</li>
<li>
On September 22, Metsera's weight loss drug project faced recent setbacks, and Pfizer's move aims to strengthen its product line. This news further boosted Metsera's stock price. The industry trend is positive, with noticeable capital inflow.
</li>
</ol>
Qualigen Therapeutics rose 117.96%. Based on recent key news:
<ol>
<li>
On September 22, Faraday Future announced a strategic investment in Qualigen Therapeutics totaling $41 million. This move propelled Qualigen's stock price up 312%, and it plans to change its name to CXC10, focusing on cryptocurrency and Web3 business.
</li>
<li>
On September 22, Qualigen announced significant personnel changes, with the CEO and CFO resigning, and Kevin Richardson appointed as interim CEO and CFO. This move did not reverse the company's difficulties, but the market remains cautious about future developments.
</li>
<li>
On September 20, Qualigen signed a securities purchase agreement with Faraday Future, which will hold over 62% of Qualigen's shares and plans to collaborate in the cryptocurrency and Web3 fields. Investment in the cryptocurrency and Web3 sectors is active
AbbVie rose 0.62%, with a trading volume of $210 million. According to recent important news:
</li>
<li>
On September 19, a significant breakthrough occurred in China's biopharmaceutical sector, attracting collaboration from international pharmaceutical companies. AbbVie signed a multi-billion dollar licensing agreement with a Chinese pharmaceutical company, driving up its stock price. Data source: DealForma report.
</li>
<li>
On September 20, the Phase I study of GUB014295, in which AbbVie is involved, progressed smoothly, potentially enhancing the company's product portfolio in the weight management field and attracting investor attention. Data source: ClinicalTrials.
</li>
<li>
On September 21, AbbVie was listed as one of the 12 best dividend-paying stocks, with its long-term investment value recognized by the market, boosting its stock price. Data source: MarketBeat. International cooperation in the biopharmaceutical industry is frequent, and innovative drugs are on the rise.
</li>
</ol>
Stocks ranked at the top of the industry by market capitalization
Amgen rose 0.22%, with a market capitalization of $154 billion. Based on recent important news:
<ol>
<li>
On September 19, Amgen's stock price increased by 2.3%, making it the company with the largest gain among the Dow components. This increase was mainly driven by the market's positive expectations for its biotechnology sector.
</li>
<li>
On September 20, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanding the treatment indications for Amgen's drug Uplizna to include the treatment of adult immunoglobulin G4-related diseases. This news propelled the stock price upward.
</li>
<li>
On September 22, market analysts maintained a hold rating on Amgen, although some analysts believe other stocks have more investment value, which exerted some pressure on the stock price. Policy changes in the biotechnology sector impact stock prices
</li>
</ol>

THAR

CNTN

Tharimmune fell 21.69%; Metsera rose 62.76%, with a transaction volume of USD 494 million; Qualigen Therapeutics rose 117.96%, with a transaction volume of USD 379 million; AbbVie rose 0.62%, with a transaction volume of USD 210 million; Amgen rose 0.22%, with a market value of USD 154 billion

U.S. stock market update: Tharimmune down 21.69%